RBC Downgrades Myriad Genetics (MYGN) to Sector Perform
More News related to MYGN
- Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Myriad Genetics (MYGN) Misses Q1 EPS by 3c
- Myriad Genetics Reports First Quarter Fiscal 2010 Financial Results
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
RBC Capital downgrades Myriad Genetics (Nasdaq: MYGN) from Outperform to Sector Perform.
Myriad announced last night that based on preliminary estimates, it anticipates reporting total molecular diagnostic revenue, which represents the bulk of the Company's revenue, of approximately $86 million for Q4. The Street was looking for Q4 sales of $91.63 million.
Shares of Myriad Genetics are currently down 26.5% to $26.24.
Also weighing on the stock, numerous analysts are out with downgrades or price target reductions on the stock this morning. To stay up-to-date on all the upgrades/downgrades, visit our Analyst Ratings page.
Myriad Genetics, Inc., a healthcare company, engages in the development and marketing of molecular diagnostic and therapeutic products.
Related Categories
DowngradesStocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
